Medpace Logo

For Immediate Release: October 2, 2017

Mary Kuramoto
513-579-9911 x 12523

Reinilde Heyrman, MD Joins Medpace’s Executive Leadership Team
as Vice President of Medical Affairs

CINCINNATI, OH — (October 2, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO) known for its strong therapeutic and regulatory expertise, announced that Reinilde Heyrman has joined Medpace’s executive leadership team as the Vice President of Medical Affairs, effective September 18. Dr. Heyrman will be working alongside Dr. Daniel O’Leary, Senior Vice President of Medical Affairs, in providing medical leadership to Medpace’s core therapeutically-focused medical doctors. The addition of Dr. Heyrman further strengthens the company’s unique physician-led approach to clinical development.

Dr. Heyrman brings a wealth of expertise to her new role, including 20+ years of experience in clinical development of new compounds. Prior to joining Medpace, she held a number of executive level roles at pharmaceutical companies where she was responsible for all clinical and scientific aspects of clinical development. Most recently, she owned her own consulting firm where she provided advice to clients on everything from portfolio management to submission documents. Her diverse background includes clinical development work in respiratory diseases, cardiovascular, metabolic, orphan disease, pediatrics, and infectious diseases. She earned her medical degree as well as completed her post-graduate training at the University of Antwerp in Belgium.

“I’ve worked with Medpace from the sponsor side and never found a better partner to reach our common goal of high quality and timely development work for a safe and effective therapeutic,” commented Dr. Heyrman. “Being part of the Medpace team is completely in line with my fundamental desire to help as many patients as possible live better lives. My passion and dedication to patients and science will be more than matched by that of my colleagues here at Medpace and I look forward to working with sponsors and our teams to advance exciting new therapeutics.”


Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.